[PDF][PDF] RETRACTED: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell …

X Zhang, X Zhao, W Fiskus, J Lin, T Lwin, R Rao… - Cancer cell, 2012 - cell.com
X Zhang, X Zhao, W Fiskus, J Lin, T Lwin, R Rao, Y Zhang, JC Chan, K Fu, VE Marquez…
Cancer cell, 2012cell.com
We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3,
and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate
that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2.
MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and
EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback.
Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 …
Summary
We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback. Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo. These findings define a MYC-mediated miRNA repression mechanism, shed light on MYC lymphomagenesis mechanisms, and reveal promising therapeutic targets for aggressive B-cell malignancies.
cell.com